nach oben

Neurological Sciences

Erschienen in:

30.04.2019 | Original Article

Attenuation of vincristine-induced neuropathy by synthetic cyclohexenone-functionalized derivative in mice model

verfasst von: Jawad Khan, Gowhar Ali, Rasool Khan, Rahim Ullah, Salim Ullah

Erschienen in: Neurological Sciences | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Vincristine (VCR) is a well-known anticancer drug which frequently induced painful neuropathy and impairs the quality of life of patients. The present study was designed to investigate the alleviative potential of a novel cyclohexenone derivative (CHD), i.e., ethyl 6-(4-methoxyphenyl)-2-oxo-4-phenylcyclohexe-3-enecarboxylate, against VCR-induced neuropathic pain in mice model. VCR was administered intraperitoneally for 10 days in two cycles to induce neuropathic pain. Static and dynamic mechanical allodynia was evaluated using von Frey hair filaments and cotton buds, respectively. Paw thermal hyperalgesia was determined through a hot plate analgesiometer. The tail cold immersion hyperalgesia and paw cold allodynia were determined by available standard protocols. The formalin nociception was induced via subplantar injection of formalin. The antioxidant potential was evaluated via 2,2-diphenyl-1-picrylhydrazyl free radical scavenging activity. The outcome of this study revealed that CHD (30–45 mg/kg) and gabapentin (75 mg/kg) significantly enhanced the paw withdrawal threshold (PWT) and paw withdrawal latency (PWL) in static and dynamic allodynia, respectively, and increased the PWL in thermal hyperalgesia and tail withdrawal latency (TWL) as compared to the VCR-treated group. CHD significantly augmented the paw withdrawal duration (PWD) in paw cold allodynia, while the same compound only increased the paw elevation and paw licking in the delayed phase of formalin nociception. Moreover, CHD significantly inhibited the DPPH free radical scavenging action (IC₅₀ = 56), butylated hydroxytoluene (BHT) (IC₅₀ = 39), and ascorbic acid (IC₅₀ = 2.93). In conclusion, CHD exhibited a profile of potential attenuative effect against the VCR-induced neuropathic pain which might be attributed to its possible antinociceptive and antioxidant effect.

Merskey H (1986) Classification of chronic pain: description of chronic pain syndromes and definitions of pain terms. Pain 3:216–221

Rasmussen PV, Sindrup SH, Jensen TS, Bach FW (2004) Symptoms and signs in patients with suspected neuropathic pain. Pain 110:461–469CrossRefPubMed

Woolf CJ, Mannion RJ (1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353:1959–1964. https://doi.org/10.1016/S0140-6736(99)01307-0 CrossRefPubMed

Poupon P, Monlun M, Alexandre L, Blanco L, Rigalleau V (2018) Sudomotor function in diabetic peripheral artery disease: a role for diabetic neuropathy? Neurol Sci 39:191–192. https://doi.org/10.1007/s10072-017-3103-6 CrossRefPubMed

Cazzato D, Dalla Bella E, Saveri P, Taroni F, Marucci G, Lauria G (2019) Late-onset and fast progressive neuropathy and cardiomyopathy in Val32Ala transthyretin gene mutation. Neurol Sci:1–3. https://doi.org/10.1007/s10072-019-3716-z

Ali G, Subhan F, Abbas M, Zeb J, Shahid M, Sewell RD (2015) A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. Naunyn Schmiedeberg's Arch Pharmacol 388:1129–1140. https://doi.org/10.1007/s00210-015-1145-y CrossRef

Gutiérrez-Gutiérrez G, Sereno M, Miralles A, Casado-Sáenz E, Gutiérrez-Rivas E (2010) Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 12:81–91. https://doi.org/10.1007/S12094-010-0474-z CrossRefPubMed

Ito T, Mochida A, Saito K, Nishi K, Sasaki S, Hisada T, Morinari H, Nakahara K, Tahara M, Masuda S (2002) An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years. Nihon Kokyuki Gakkai zasshi 40:71–76PubMed

Bromberg M (2000) Peripheral neurotoxic disorders. Clin Neurobehav Toxicol 18:681–689

10.

Tanner KD, Levine JD, Topp KS (1998) Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 395:481–492. https://doi.org/10.1002/(SICI)1096-9861(19980615)395:4<481::AID-CNE5>3.0.CO;2-Y CrossRefPubMed

11.

Tanner KD, Reichling DB, Levine JD (1998) Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci 18:6480–6491. https://doi.org/10.1523/JNEUROSCI.18-16-06480.1998 CrossRefPubMedPubMedCentral

12.

Topp KS, Tanner KD, Levine JD (2000) Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 424:563–576. https://doi.org/10.1002/1096-9861(20000904)424:4<563::AID-CNE1>3.0.CO;2-U CrossRefPubMed

13.

Aley K, Reichling D, Levine J (1996) Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience 73:259–265. https://doi.org/10.1016/0306-4522(96)00020-6 CrossRefPubMed

14.

Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL (2001) Vincristine-induced allodynia in the rat. Pain 93:69–76. https://doi.org/10.1016/S0304-3959(01)00294-9 CrossRefPubMed

15.

Authier N, Gillet J-P, Fialip J, Eschalier A, Coudore F (2003) A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurotoxicology 24:797–805. https://doi.org/10.1016/S0161-813X(03)00043-3 CrossRefPubMed

16.

Jaggi AS, Singh N (2010) Differential effect of spironolactone in chronic constriction injury and vincristine-induced neuropathic pain in rats. Eur J Pharmacol 648:102–109. https://doi.org/10.1016/j.ejphar.2010.08.050 CrossRefPubMed

17.

Muthuraman A, Jaggi AS, Singh N, Singh D (2008) Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine induced painful neuropathy in rats. Eur J Pharmacol 587:104–111. https://doi.org/10.1016/j.ejphar.2008.03.042 CrossRefPubMed

18.

Dworkin RH, O’connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, Kent JL, Krane EJ, LeBel AA, Levy RM (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. In: Mayo Clin Proc. Elsevier, pp S3-S14. https://doi.org/10.4065/mcp.2009.0649

19.

Lee JNP (2010) Improving the management of neuropathic pain. Practioner 254:27–30

20.

Wiffen PJ, Collins S, McQuay HJ, Carroll D, Jadad A, Moore RA (2010) WITHDRAWN. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 1:CD001133–CD001133. https://doi.org/10.1002/14651858.CD001133.pub3 CrossRef

21.

Wamboldt C, Kapustin J (2006) Evidence-based treatment of diabetic peripheral neuropathy. J Nurse Pract 2:370–378. https://doi.org/10.1016/j.nurpra.2006.04.015 CrossRef

22.

Senguttuvan S, Nagarajan S (2010) Synthesis of 2-amino-5-aryl-5,6-dihydro-7-(naphthalen-2-yl)quinazolin-4-ols. Int J Chem 2:108CrossRef

23.

Gopalakrishnan M, Thanusu J, Kanagarajan V (2008) Synthesis and characterization of 4,6-diaryl-4,5-dihydro-2H-indazol-3-ols and 4,6-diaryl-2-phenyl-4,5-dihydro-2H-indazol-3-ols—a new series of fused indazole derivatives. Chem Heterocycl Comp 44:950–955. https://doi.org/10.1007/s10593-008-0137-y CrossRef

24.

Johnson T, Pultar F, Menke F, Lautens M (2016) Palladium-catalyzed α-arylation of vinylogous esters for the synthesis of γ, γ-disubstituted cyclohexenones. Org Lett 18:6488–6491. https://doi.org/10.1021/acs.orglett.6b03394 CrossRefPubMed

25.

Liu D, Yu W, Li J, Pang C, Zhao L (2013) Novel 2-(E)-substituted benzylidene-6-(N-substituted aminomethyl) cyclohexanones and cyclohexanols as analgesic and anti-inflammatory agents. Med Chem Res 22:3779–3786. https://doi.org/10.1007/s00044-012-0362-x CrossRef

26.

Wang Y, Yu C, Pan Y, Li J, Zhang Y, Ye F, Yang S, Zhang H, Li X, Liang G (2011) A novel compound C12 inhibits inflammatory cytokine production and protects from inflammatory injury in vivo. PLoS One 6:e24377. https://doi.org/10.1371/journal.pone.0024377 CrossRefPubMedPubMedCentral

27.

Sheorey R, Thangathiruppathy A, Alagarsamy V (2016) Synthesis and pharmacological evaluation of 3-propyl-2-substitutedamino-3H-quinazolin-4-ones as analgesic and anti-inflammatory agents. J Heterocycl Chem 53:1371–1377. https://doi.org/10.1002/jhet.1973 CrossRef

28.

Lednicer D, Von Voigtlander PF, Emmert DE (1981) 4-Aryl-4-aminocyclohexanones and their derivatives, a novel class of analgesics. 3. M-hydroxyphenyl derivatives. J Med Chem 24:341–346. https://doi.org/10.1021/jm00135a019 CrossRefPubMed

29.

Lednicer D, VonVoigtlander PF, Emmert DE (1981) 4-Amino-4-arylcyclohexanones and their derivatives: a novel class of analgesics. 2. Modification of the carbonyl function. J Med Chem 24:404–408. https://doi.org/10.1021/jm00136a010 CrossRefPubMed

30.

Ming-Tatt L, Khalivulla SI, Akhtar MN, Lajis N, Perimal EK, Akira A, Ali DI, Sulaiman MR (2013) Anti-hyperalgesic effect of a benzilidine-cyclohexanone analogue on a mouse model of chronic constriction injury-induced neuropathic pain: participation of the κ-opioid receptor and KATP. Pharmacol Biochem Behav 114:58–63. https://doi.org/10.1016/j.pbb.2013.10.019 CrossRefPubMed

31.

Ahmadi A, Khalili M, Hajikhani R, Hosseini H, Afshin N, Nahri-Niknafs B (2012) Synthesis and study the analgesic effects of new analogues of ketamine on female Wistar rats. Med Chem 8:246–251. https://doi.org/10.2174/157340612800493683 CrossRefPubMed

32.

Ming-Tatt L, Khalivulla SI, Akhtar MN, Mohamad AS, Perimal EK, Khalid MH, Akira A, Lajis N, Israf DA, Sulaiman MR (2012) Antinociceptive activity of a synthetic curcuminoid analogue, 2,6-bis-(4-hydroxy-3-methoxybenzylidene) cyclohexanone, on nociception-induced models in mice. Basic Clin Pharmacol Toxicol 110:275–282. https://doi.org/10.1111/j.1742-7843.2011.00804.x CrossRefPubMed

33.

Weng H-R, Cordella J, Dougherty P (2003) Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 103:131–138CrossRefPubMed

34.

Siau C, Bennett GJ (2006) Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 102:1485–1490. https://doi.org/10.1213/01.ane.0000204318.35194.ed CrossRefPubMedPubMedCentral

35.

Chaplan S, Bach F, Pogrel J, Chung J, Yaksh T (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55–63CrossRefPubMed

36.

Field MJ, McCleary S, Hughes J, Singh L (1999) Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80:391–398CrossRefPubMed

37.

Nakazato-Imasato E, Tanimoto-Mori S, Kurebayashi Y (2009) Effect of mexiletine on dynamic allodynia induced by chronic constriction injury of the sciatic nerve in rats. J Vet Med Sci 71:991–994CrossRefPubMed

38.

Ahmad N, Subhan F, Islam NU, Shahid M, Rahman FU, Sewell RD (2017) Gabapentin and its salicylaldehyde derivative alleviate allodynia and hypoalgesia in a cisplatin-induced neuropathic pain model. Eur J Pharmacol 814:302–312. https://doi.org/10.1016/j.ejphar.2017.08.040 CrossRefPubMed

39.

Necker R, Hellon R (1977) Noxious thermal input from the rat tail: modulation by descending inhibitory influences. Pain 4:231–242CrossRef

40.

Decosterd I, Woolf CJ (2000) Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87:149–158CrossRefPubMed

41.

Geisler S, Doan RA, Strickland A, Huang X, Milbrandt J, DiAntonio A (2016) Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain 139:3092–3108. https://doi.org/10.1093/brain/aww251 CrossRefPubMedPubMedCentral

42.

Abad ANA, Nouri MHK, Tavakkoli F (2011) Effect of Salvia officinalis hydroalcoholic extract on vincristine-induced neuropathy in mice. Chin J Nat Med 9:354–358. https://doi.org/10.3724/SP.J.1009.2011.00354 CrossRef

43.

Samshuddin S, Narayana B, Sarojini BK, Madhu LN (2013) A study on the reactions of alkyl 4,6-bis (4-fluorophenyl)-2-oxocyclohex-3-ene-1-carboxylate and in vitro antioxidant activity of derivatives. Med Chem Res 22:3002–3011. https://doi.org/10.1007/s00044-012-0304-7 CrossRef

44.

Cata J, Weng H, Lee B, Reuben J, Dougherty P (2006) Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72:151PubMed

45.

Linglu D, Yuxiang L, Yaqiong X, Ru Z, Lin M, Shaoju J, Juan D, Tao S, Jianqiang Y (2014) Antinociceptive effect of matrine on vincristine-induced neuropathic pain model in mice. Neurol Sci 35:815–821. https://doi.org/10.1007/s10072-013-1603-6 CrossRefPubMed

46.

Hur W, Chung JY, Choi PK, Kang HG (2019) Uremia presented as acute cranial neuropathy. Neurol Sci:1–3. https://doi.org/10.1007/s10072-019-03741-6

47.

Vitet L, Patte-Mensah C, Boujedaini N, Mensah-Nyagan A-G, Meyer L (2018) Beneficial effects of Gelsemium-based treatment against paclitaxel-induced painful symptoms. Neurol Sci 39:2183–2196. https://doi.org/10.1007/s10072-018-3575-z CrossRefPubMed

48.

Jaggi AS, Jain V, Singh N (2011) Animal models of neuropathic pain. Fundam Clin Pharmacol 25:1–28. https://doi.org/10.1111/j.1472-8206.2009.00801.x CrossRefPubMed

49.

Villani F, Busia A, Villani M, Vismara C, Viviani S, Bonfante V (2008) Serum cytokine in response to chemo-radiotherapy for Hodgkin’s disease. Tumori 94:803–808CrossRefPubMed

50.

Starobova H, Vetter I (2017) Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci 10:174. https://doi.org/10.3389/fnmol.2017.00174 CrossRefPubMedPubMedCentral

51.

Grisold W, Cavaletti G, Windebank AJ (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 14:iv45–iv54. https://doi.org/10.1093/neuonc/nos203 CrossRefPubMedPubMedCentral

52.

Jaggi AS, Singh N (2012) Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 291:1–9. https://doi.org/10.1016/j.tox.2011.10.019 CrossRefPubMed

53.

Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG (2010) Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy. Cell Mol Life Sci 67:3017–3034. https://doi.org/10.1007/s00018-010-0372-0 CrossRefPubMed

54.

Dworkin RH, O’connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132(3):237–251CrossRefPubMed

55.

Mora E, Smith EML, Donohoe C, Hertz DL (2016) Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res 6:2416PubMedPubMedCentral

56.

Lynch JJ III, Wade CL, Zhong CM, Mikusa JP, Honore P (2004) Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 110(1–2):56–63CrossRefPubMed

57.

Flatters SJ, Bennett GJ (2004) Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 109:150–161. https://doi.org/10.1016/j.pain.2004.01.029 CrossRefPubMed

58.

Bhalla S, Singh N, Jaggi AS (2015) Dose-related neuropathic and anti-neuropathic effects of simvastatin in vincristine-induced neuropathic pain in rats. Food Chem Toxicol 80:32–40. https://doi.org/10.1016/j.fct.2015.02.016 CrossRefPubMed

59.

Bang S, Kim YS, Jeong SR (2016) Anti-allodynic effect of theoesberiven F in a vincristine-induced neuropathy model. Exp Ther Med 12:799–803. https://doi.org/10.3892/etm.2016.3396 CrossRefPubMedPubMedCentral

60.

Geis C, Beyreuther BK, Stöhr T, Sommer C (2011) Lacosamide has protective disease modifying properties in experimental vincristine neuropathy. Neuropharmacology 61:600–607. https://doi.org/10.1016/j.neuropharm.2011.05.001 CrossRefPubMed

61.

Xiao WH, Bennett GJ (2008) Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 135:262–270. https://doi.org/10.1016/j.pain.2007.06.001 CrossRefPubMed

62.

Mika J, Zychowska M, Popiolek-Barczyk K, Rojewska E, Przewlocka B (2013) Importance of glial activation in neuropathic pain. Eur J Pharmacol 716:106–119. https://doi.org/10.1016/j.ejphar.2013.01.072 CrossRefPubMed

63.

Carozzi V, Canta A, Chiorazzi A (2015) Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 596:90–107. https://doi.org/10.1016/j.neulet.2014.10.014 CrossRefPubMed

64.

Sisignano M, Baron R, Scholich K, Geisslinger G (2014) Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol 10:694–707. https://doi.org/10.1038/nrneurol.2014.211 CrossRefPubMed

65.

Miyagawa M, Watanabe T, Saito M, Luu B, Yamada M, Suzuki H (2010) Use of cyclohexenone derivatives in the manufacture of a medicament for treating diabetic complications. Google Patents

66.

Yoshizawa T, Hayashi Y, Yoshida A, Ito Y, Yamada S, Takahashi S (2012) 107 therapeutic effects of the cyclohexenone derivative tac-302 on the bladder dysfunction in streptozotocin (STZ)-induced diabetic rats. J Urol 187:e43. https://doi.org/10.1016/j.juro.2012.02.155 CrossRef

67.

Ashalatha B, Narayana B, Vijaya Raj K (2009) Synthesis and characterization of some novel 3-bromo-2-acetylthiophene chalcones and biological evaluation of their ethyl-4-(3-bromothien-2-yl)-2-oxo-6-(aryl) cyclohex-3-ene-1-carboxylate derivatives. Phosphorus Sulfur Silicon Relat Elem 184:1904–1919. https://doi.org/10.1080/10426500802414189 CrossRef

68.

Kato T, Ishii H, Kawai K, Sawa Y (1984) Synthesis and analgesic activity of cyclohexenylmethylamines and related compounds. Chem Pharm Bull 32:2279–2289CrossRef

69.

Yaouba S, Koch A, Guantai EM, Derese S, Irungu B, Heydenreich M, Yenesew A (2018) Alkenyl cyclohexanone derivatives from Lannea rivae and Lannea schweinfurthii. Phytochem Lett 23:141–148. https://doi.org/10.1016/j.phytol.2017.12.001 CrossRef

70.

Fujioka H, Kotoku N, Sawama Y, Nagatomi Y, Kita Y (2002) Concise asymmetric synthesis of a model compound, (4S,5S,6S)-6-(2,2-dimethoxy)ethyl-4,5-epoxy-6-hydroxy-2-cyclohexenone, for the cyclohexenone core of scyphostatin. Tetrahedron Lett 43:4825–4828. https://doi.org/10.1016/S0040-4039(02)00916-4 CrossRef

71.

Hoye TR, Tennakoon MA (2000) Synthesis (and alternative proof of configuration) of the scyphostatin C (1’)-C(20’) trienoyl fragment. Organic Lett 2:1481–1483. https://doi.org/10.1021/ol0058386 CrossRef

72.

Lopes L, Pereira S, Silva L, Figueiredo K, Moura B, Almeida F, Sousa F (2009) Antinociceptive effect of topiramate in models of acute pain and diabetic neuropathy in rodents. Life Sci 84:105–110. https://doi.org/10.1016/j.lfs.2008.11.005 CrossRefPubMed

73.

Ranjithkumar R, Prathab Balaji S, Balaji B, Ramesh R, Ramanathan M (2013) Standardized aqueous Tribulus terristris (Nerunjil) extract attenuates hyperalgesia in experimentally induced diabetic neuropathic pain model: role of oxidative stress and inflammatory mediators. Phytother Res 27:1646–1657. https://doi.org/10.1002/ptr.4915 CrossRefPubMed

74.

Muthuraman A, Singh N (2011) Attenuating effect of hydroalcoholic extract of Acorus calamus in vincristine-induced painful neuropathy in rats. J Nat Med 65:480–487. https://doi.org/10.1007/s11418-011-0525-y CrossRefPubMed

75.

Muthuraman A, Singh N, Jaggi AS (2011) Protective effect of Acorus calamus L. in rat model of vincristine induced painful neuropathy: an evidence of anti-inflammatory and anti-oxidative activity. Food Chem Toxicol 49:2557–2563. https://doi.org/10.1016/j.fct.2011.06.069 CrossRefPubMed

76.

Kim HK, Zhang YP, Gwak YS, Abdi S (2010) Phenyl N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. Anesthesiology 112:432–439. https://doi.org/10.1097/ALN.0b013e3181ca31bd CrossRefPubMed

77.

Okoth DA, Akala HM, Johnson JD, Koorbanally NA (2016) Alkyl phenols, alkenyl cyclohexenones and other phytochemical constituents from Lannea rivae (chiov) Sacleux (Anacardiaceae) and their bioactivity. Med Chem Res 25:690–703. https://doi.org/10.1007/s00044-016-1521-2 CrossRef

78.

Mazimba O, Wale K, Loeto D, Kwape T (2014) Antioxidant and antimicrobial studies on fused-ring pyrazolones and isoxazolones. Bioorg Med Chem 22:6564–6569. https://doi.org/10.1016/j.bmc.2014.10.015 CrossRefPubMed

79.

Rose M, Kam P (2002) Gabapentin: pharmacology and its use in pain management. Anaesthesia 57:451–462CrossRefPubMed

80.

Bennett MI, Simpson KH (2004) Gabapentin in the treatment of neuropathic pain. Palliat Med 18:5–11. https://doi.org/10.1191/0269216304pm845ra CrossRefPubMed

81.

Gilron I, Flatters SJ (2006) Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manag 11:16A–29A. https://doi.org/10.1155/2006/651712 CrossRef

Titel: Attenuation of vincristine-induced neuropathy by synthetic cyclohexenone-functionalized derivative in mice model
verfasst von: Jawad Khan
Gowhar Ali
Rasool Khan
Rahim Ullah
Salim Ullah
Publikationsdatum: 30.04.2019
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 9/2019
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-019-03884-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

A semi-quantitative sport-specific assessment of recurrent traumatic brain injury: the TraQ questionnaire and its application in American football

Analyzing theory of mind impairment in patients with behavioral variant frontotemporal dementia

Sixth cranial nerve palsy and ipsilateral segmental carotid arteritis after tooth alveolectomy

Motor reaction time and accuracy in patients with multiple sclerosis: effects of an active computerized training program

Ischemic stroke due to sarcoidosis: the arterial wall enhancement on magnetic resonance imaging